nrti

Azvudine (FNC) is a potent nucleoside reverse transcriptase inhibitor (NRTI), with antiviral activity on HIV, HBV and HCV. Azvudine inhibits NRTI-resistant viral strains. Azvudine exerts highly potent inhibition on HIV-1 (EC50s ranging from 0.03 to 6.92 nM) and HIV-2 (EC50s ranging from 0.018 to 0.025 nM).

NNRTIs-IN-3 (compound 8) is an HIV-1 non-nucleoside reverse transcriptase inhibitor, displaying potent efficacy with an EC50 value of 0.01 µM [1].

NNRTIs-IN-1 is a potent non-nucleoside reverse transcriptase inhibitor (NNRTI) with notable anti-resistance efficacy, effectively inhibiting both the wild-type HIV-1 and five mutant strains at EC50 values within the nanomolar range. This compound also exhibits favorable pharmacokinetic properties [1].

Emtricitabine is a nucleoside reverse transcriptase inhibitor with anti-human immunodeficiency virus (HIV) and hepatitis B virus activity, with an EC50 value of 0.01 µM in PBMC cells, and can be used to study HIV infection.

Stampidine can prevent the sexual transmission of HIV-1. It exhibited remarkable subnanomolar to low nanomolar in vitro antiretroviral potency against nucleoside reverse transcriptase inhibitor-resistant primary clinical HIV isolates, non-nucleoside RT-re

NNRT-IN-6 (Compound 13a) is a non-nucleoside reverse transcriptase inhibitor (NNRT) used to inhibit HIV-1 reverse transcriptase (HIV-1RT), with an IC50 of 0.41 μM. It effectively suppresses both wild-type HIV-1 and mutants L100I, K103N, Y181C, Y188L, E138K, F227L/V106A, and RES056, with an EC50 range of 6.2-250 nM.

NNRT-IN-4 (Compound 10p) is an inhibitor of non-nucleoside reverse transcriptase (NNRT) with an IC50 of 0.713 µM for HIV-1RT. It exhibits antiviral activity against both wild-type and mutant strains of HIV-1, with an EC50 ranging from 6 to 63 nM. NNRT-IN-4 shows weak inhibitory activity on hERG (IC50=25.9 µM) and CYP enzymes (IC50>50 µM). In mice, NNRT-IN-4 demonstrates good tolerance and safety at 2 g/kg.

NNRT-IN-10 is a potent, selective, and orally bioavailable non-nucleoside reverse transcriptase inhibitor (NNRTI) for HIV-1. The compound exhibits EC50 values ranging from 1.16 to 18.3 nM against HIV and its variants. NNRT-IN-10 has favorable pharmacokinetic properties and safety profile, making it suitable for research on AIDS caused by HIV-1.

NNRT-IN-8 (compound 9K) is a potent non-nucleoside reverse transcriptase inhibitor, exhibiting EC50 values of 0.0014, 0.0041, and 0.0077 µM against HIV-1WT, K103N, and E138K, respectively.

NNRT-IN-9 (Compound EG28) is a non-nucleoside reverse transcriptase inhibitor (NNRT). It demonstrates strong antiviral and resistance-fighting activity against wild-type (WT) and various clinically relevant mutant strains (E138K and K103N + Y181C) of HIV-1, with EC50 values of 55 nM, 67 nM, and 3910 nM, respectively. NNRT-IN-9 is applicable in acquired immunodeficiency syndrome (AIDS) research.

NNRT-IN-11 (14l) is a potent non-nucleoside reverse transcriptase (NNRT) inhibitor, exhibiting EC50 values ranging from 6.50 to 52.9 nM against both wild-type (WT) and a range of HIV-1 mutant strains. NNRT-IN-11 demonstrates antiviral properties.

Rilpivirine (R278474) is a diarylpyrimidine derivative and reverse transcriptase inhibitor with antiviral activity against HIV-1 that is used in the treatment of HIV infections.

Delavirdine mesylate (BHAP-U 90152 (mesylate)) is a non-nucleoside reverse transcriptase inhibitor (NNRTI).

Lersivirine (UK-453061)(UK 453061) is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) under development for HIV infection therapy.

NNRT-IN-2 (compound 7w) is an orally administered non-nucleoside reverse transcriptase inhibitor (NNRTI) that effectively suppresses both wild-type HIV-1 and various mutant strains. It inhibits HIV-1 reverse transcriptase with an EC 50 value of 22 nM. Additionally, NNRT-IN-2 exhibits insensitivity to CYP and hERG, demonstrating favorable safety and pharmacokinetic profiles [1].

Zalcitabine (Dideoxycytidine)(Dideoxycytidine;ddC; 2', 3'-Dideoxycytidine) is a nucleoside analog reverse transcriptase inhibitor (NRTI); At low concentrations, It can potently inhibit HIV replication by binding to reverse transcriptase terminated synthesis of viral DNA chain.

Tenofovir alafenamide (GS-7340) is a nucleotide reverse transcriptase inhibitor (NRTI) and a novel ester prodrug of the antiretroviral tenofovir.

AZT-PMPA, an aryl phosphate derivative of AZT and a nucleoside analogue, demonstrates anti-HIV activity[1]. As a nucleoside reverse transcriptase inhibitor (NRTI), AZT-PMPA targets HIV infection effectively[2].

Tizoxanide (Desacetyl-nitazoxanide) is a metabolite of lamivudine. Lamivudine (2', 3'-dideoxy-3'-thiacytidine, commonly called 3TC) is a potent nucleoside analog reverse transcriptase inhibitor (nRTI).

Azvudine hydrochloride (RO-0622) is a potent nucleoside reverse transcriptase inhibitor (NRTI) with strong antiviral effects against HIV, HBV, and HCV. It demonstrates highly potent inhibition of HIV-1 (EC50 ranging from 0.03 to 6.92 nM) and HIV-2 (EC50 ranging from 0.018 to 0.025 nM), and effectively inhibits NRTI-resistant viral strains.

FNC-TP, the intracellular active form of FNC, is a potent nucleoside reverse transcriptase inhibitor (NRTI) with broad-spectrum antiviral activity against HIV, HBV, and HCV.

Stavudine sodium (d4T), an orally active nucleoside reverse transcriptase inhibitor (NRTI), demonstrates activity against both HIV-1 and HIV-2. It also inhibits mitochondrial DNA (mtDNA) replication, reduces NLRP3 inflammasome activation, modulates Amyloid-β autophagy, and induces apoptosis [1] [2] [3] [4].

Lamivudine (BCH-189) salicylate is an orally active nucleoside reverse transcriptase inhibitor (NRTI) that inhibits the reverse transcriptase activity of both HIV-1/2 and hepatitis B virus, while also demonstrating the ability to penetrate the central nervous system [1] [2].

FNC-TP trisodium is the intracellularly active form of FNC, a potent inhibitor of nucleoside reverse transcriptase (NRTI) that exhibits antiviral effects against HIV, HBV and HCV.